Additionally, the 36-month beta value for TARS is 0.99. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for TARS is 33.09M and currently, short sellers hold a 22.19% ratio of that float. The average trading volume of TARS on March 13, 2025 was 627.99K shares.
TARS) stock’s latest price update
The stock price of Tarsus Pharmaceuticals Inc (NASDAQ: TARS) has plunged by -2.66 when compared to previous closing price of 47.10, but the company has seen a 5.23% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-03-12 that IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the pricing of an upsized underwritten public offering of 2,808,988 shares of its common stock at a public offering price of $44.50 per share. In addition, Tarsus has granted the underwriters a 30-day option to purchase up to an additional 421,348 shares of its common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Tarsus, are expected to be approximately $125.0 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on March 14, 2025, subject to the satisfaction of customary closing conditions.
TARS’s Market Performance
TARS’s stock has risen by 5.23% in the past week, with a monthly drop of -10.49% and a quarterly drop of -9.50%. The volatility ratio for the week is 5.90% while the volatility levels for the last 30 days are 5.80% for Tarsus Pharmaceuticals Inc The simple moving average for the past 20 days is -0.69% for TARS’s stock, with a 17.45% simple moving average for the past 200 days.
Analysts’ Opinion of TARS
Many brokerage firms have already submitted their reports for TARS stocks, with Goldman repeating the rating for TARS by listing it as a “Neutral.” The predicted price for TARS in the upcoming period, according to Goldman is $19 based on the research report published on November 20, 2023 of the previous year 2023.
William Blair, on the other hand, stated in their research note that they expect to see TARS reach a price target of $44. The rating they have provided for TARS stocks is “Outperform” according to the report published on July 18th, 2023.
TARS Trading at -7.41% from the 50-Day Moving Average
After a stumble in the market that brought TARS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -19.96% of loss for the given period.
Volatility was left at 5.80%, however, over the last 30 days, the volatility rate increased by 5.90%, as shares sank -12.03% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -16.30% lower at present.
During the last 5 trading sessions, TARS rose by +5.66%, which changed the moving average for the period of 200-days by +27.31% in comparison to the 20-day moving average, which settled at $46.18. In addition, Tarsus Pharmaceuticals Inc saw -17.20% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TARS starting from LINK WILLIAM J PHD, who sale 35,000 shares at the price of $26.08 back on Aug 12 ’24. After this action, LINK WILLIAM J PHD now owns 0 shares of Tarsus Pharmaceuticals Inc, valued at $912,961 using the latest closing price.
FLYING L PARTNERS XI LLC, the Director of Tarsus Pharmaceuticals Inc, proposed sale 35,000 shares at $26.85 during a trade that took place back on Aug 12 ’24, which means that FLYING L PARTNERS XI LLC is holding shares at $939,750 based on the most recent closing price.
Stock Fundamentals for TARS
Current profitability levels for the company are sitting at:
- -0.66 for the present operating margin
- 0.93 for the gross margin
The net margin for Tarsus Pharmaceuticals Inc stands at -0.63. The total capital return value is set at -0.41. Equity return is now at value -54.83, with -35.91 for asset returns.
Based on Tarsus Pharmaceuticals Inc (TARS), the company’s capital structure generated 0.24 points at debt to capital in total, while cash flow to debt ratio is standing at -1.15. The debt to equity ratio resting at 0.32. The interest coverage ratio of the stock is -15.64.
Currently, EBITDA for the company is -106.88 million with net debt to EBITDA at 0.21. When we switch over and look at the enterprise to sales, we see a ratio of 9.54. The receivables turnover for the company is 3.81for trailing twelve months and the total asset turnover is 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.42.
Conclusion
In conclusion, Tarsus Pharmaceuticals Inc (TARS) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
